Allergan Rating Reiterated by TheStreet (AGN)
Allergan (NYSE: AGN)‘s stock had its “buy” rating reiterated by equities research analysts at TheStreet in a research note issued to investors on Tuesday.
The analysts wrote, “Allergan (AGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of A+ . The company’s strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
Other equities research analysts have also recently issued reports about the stock. Analysts at Buckingham Research downgraded shares of Allergan from a “buy” rating to a “neutral” rating in a research note to investors on Thursday, March 7th. They now have a $120.00 price target on the stock. Separately, analysts at SunTrust reiterated a “buy” rating on shares of Allergan in a research note to investors on Thursday, February 21st. They now have a $121.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Allergan in a research note to investors on Thursday, February 7th. They now have a $114.00 price target on the stock.
Nineteen research analysts have rated the stock with a buy rating, two have assigned an overweight rating, and eight have given a hold rating to the company. The company currently has an average rating of “overweight” and a consensus target price of $114.77.
Shares of Allergan opened at 110.49 on Tuesday. Allergan has a one year low of $81.28 and a one year high of $111.84. The stock’s 50-day moving average is currently $107.5. The company has a market cap of $32.935 billion and a P/E ratio of 30.86.
Allergan last issued its quarterly earnings data on Tuesday, February 5th. The company reported $1.15 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.20 by $0.05. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.51 million. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 7.6% on a year-over-year basis. Allergan has set its Q1 guidance at $0.94-0.96 EPS and its FY13 guidance at $4.75-4.83 EPS. On average, analysts predict that Allergan will post $4.76 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, March 21st. Shareholders of record on Thursday, February 28th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.18%. The ex-dividend date of this dividend is Tuesday, February 26th.
Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.